Market Growth Driven by High Prevalence of Infectious Diseases, Government Healthcare Initiatives, and Increasing Quality Diagnostics Demand ...

The twice-yearly shot lenacapavir, sold under the name Yeztugo, reportedly nearly eliminated new HIV infections in studies of ...